AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$ZOMDF

Zomedica Corp. (ZOMDF): Submission of Matters to a Vote of Security Holders

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. zom_8k.htm 0001684144 false 0001684144 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da

Original reporting
SEC EDGAR 8-K
Published Jun 11, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ZOMDF
Neutral
medium confidence
Mentioned
$ZOMDF
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ZOMDFNeutralLow
01

Why it matters

Confirms governance approvals (directors elected; Grant Thornton ratified) and a governance dissent point (executive compensation advisory vote not approved).

02

Market read

Traders may monitor for follow-on proxy/compensation actions, but this disclosure alone is unlikely to drive a major repricing.

03

What to watch

Because the vote is advisory and non-binding, traders should avoid over-weighting it versus any upcoming earnings, financing, or clinical/operational catalysts not present in this filing.

Relevance 6/10Novelty 3/10Timing: Filed June 11, 2026 after June 10 annual meeting vote results.

Background

The filing reports final results from Zomedica’s June 10, 2026 annual meeting (SEC 8-K Item 5.07).

Company-level read

Ticker impact

$ZOMDFNeutralMedium confidence
Context

Zomedica shareholders voted on director elections, auditor ratification, and an advisory say-on-pay proposal, with proposal 3 failing.

Expected impact

Likely limited near-term price impact; any effect would be sentiment/overhang-driven rather than a fundamental change.

Evidence & confidence

This is a routine post-vote disclosure (8-K Item 5.07) with no new financial guidance, contracts, or regulatory action; the only notable item is the failed non-binding compensation advisory vote.

Market effects

Sector

Minimal; this is company-specific governance mechanics rather than a sector-wide regulatory or operational change.

Regional

Minimal; no geographic operational shift is disclosed.

Global

Minimal; no cross-border deal, trial, or regulatory development is mentioned.

Counterpoint

What could challenge this read

The failed say-on-pay vote could be a signal of shareholder dissatisfaction that may precede management changes or compensation restructuring, which could matter later even if the immediate impact is small.

Key entities

  • issuer
    Zomedica Corp.

    OTC-listed company reporting annual meeting vote outcomes on directors, auditors, and say-on-pay.

  • auditor
    Grant Thornton LLP

    Ratified as independent registered public accounting firm for fiscal year ended Dec. 31, 2026.

Read at source← All news

Related articles

$ZOMDFMed

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity Zomedica surpasses $9 million in quarterly revenue for the second quarter in a row while extending its record of consecutive ye

SEC EDGAR 8-K
$ZOMDFMedAI 9/10

Zomedica Corp.: Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (OTCQB:ZOMDF) reported record Q2 2026 revenue of $9.5 million, up 37% year over year, with gross margin of 64%. Operating expenses fell 20% to $10.1 million and cash burn improved 38% to $3.4 million. The company said liquidity totaled $44.1 million and cited growth in Diagnostics, Therapeutic Devices, and Development Services.

finanznachrichten.de
$ZOMDFMed

Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity

Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-ov

SEC EDGAR 8-K
$WDSMed

Woodside Energy Group Unveils New Payout Policy, Targets $40 Billion in Cash Flow

Woodside Energy Group (WDS) announced a new payout policy and targets $40 billion in cash flow. Key projects include Scarborough (99% complete, first LNG cargo in 2026), Trion (71% complete, first oil in 2028), and Louisiana LNG (32% complete, first LNG in 2029). The company aims for 10% ROACE from base business and committed projects, with cost reductions and portfolio management to lift returns.

finance.yahoo.com
$NKEMed

FitLab Files Chapter 11 After Nike Deal Ends

FitLab and affiliates filed for Chapter 11 on Oct. 26, listing $10M-$50M in assets and over $100M in debts. The filing follows the end of a partnership with Nike, which led to financial strain. FitLab plans to sell assets and exit leases during the bankruptcy process. Nike is also restructuring to cut costs.

briefs.co